# TFC Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tfc-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.tfctx.com
- Latest round: Seed (May 16, 2023)
- Investors on record: 4

## About

Founded in 2022 and based in New York, US, TFC Therapeutics, Inc. operates as a biotechnology company that develops novel biologic drugs for the treatment of cancer and to prevent its recurrence. In August 2023, TFC Therapeutics, Inc. raised an undisclosed amount of venture funding led by ARCH Venture Partners, with participation from Alexandria Equities, Alumni Ventures Group, and Breakout Labs.

TFC offers various biologics designed for the treatment of cancer recurrence and metastasis by targeting and eradicating resilient cancer cells responsible for recurrence and metastasis. The company's platform eliminates tumour macrophage hybrid (TMH) cells, which are prevalent in the bloodstream of cancer patients and linked to metastasis, resistance to conventional therapies, relapse, and poor prognosis.

The company plans to use the August 2023 funding to develop and commercialize advanced novel technologies and therapeutics for cancer treatment and metastasis prevention.

## Funding rounds

- Seed, May 16, 2023 — ARCH Venture Partners, Breakout Ventures, Alumni Ventures Group, Alexandria Equities

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Seed
- Breakout Ventures (https://capitalatlas.ai/funds/breakout-ventures) — Seed
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Seed
- Alexandria Equities — Seed